A Phase 4 interventional study of Ketamine and Midazolam in Refractory Status Epilepticus, sponsored by Thomas Jefferson University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-16.
Sponsored by Thomas Jefferson University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Status Epilepticus with a site in United States — 13 open to participants now, 13 under way, 2 of them phase 3. Status Epilepticus · United States.
Among the 41 studies in Status Epilepticus with a site in United States, this one is the 14th largest by planned enrollment of the 30 interventional ones that give a count, is one of 3 that started in 2025, is one of 2 in phase 4, reaches primary completion later than 4 of the 12 other live ones, and was the 38th registered.
124 studies on the registry are indexed under Status Epilepticus; 37 are open to participants now.
Browse Status Epilepticus studies →13 of the 41 studies in Status Epilepticus with a site in United States are open now. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 1+
Boston Medical Center · Sites in United States
Ages 21+
University of California, San Francisco · Sites in United States
Ages 18+
Nationwide Children's Hospital · Sites in United States
Ages 30 days–18 yrs
University of California, San Francisco · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 29 Status Epilepticus studies recruiting now, 16 (55%) set no upper age limit and 8 (28%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 8 · Phase 3 11 · Phase 4 2
First in 2005; this study’s year is marked. 3 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is below the median of 80 across 75 interventional studies indexed under Status Epilepticus.
Median enrollment 35 across the 30 interventional studies, 300 across the 11 observational. Of the 26 that completed or were terminated, 12 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 41 have an industry lead sponsor. The 10 most frequent:
Thomas Jefferson University is the lead sponsor of 394 studies on the registry; 69 are open to participants now.
Of its 45 completed or terminated interventional studies of FDA-regulated products, 21 (47%) have results posted.
Thomas Jefferson University has 1 study filed under Status Epilepticus — fewer than ten, so there is no comparison to draw.
5 of the studies in Status Epilepticus with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06564662Children's Hospital at MontefioreRapid-Response EEG in Children With Suspected Status Epilepticus | 2026-12-08 |
| NCT06194747Nationwide Children's HospitalImproving Status Epilepticus Treatment Times | 2027-03-31 |
| NCT06401707University of California, San FranciscoPeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest | 2027-05-20 |
| NCT07177235Thomas Jefferson UniversityKetamine for the Treatment of Refractory Status Epilepticus | 2027-07 |
| NCT05851391University of California, San FranciscobuRst-supprESsion TO Stop Refractory Status Epilepticus Post-cardiac Arrest | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 41 studies in Status Epilepticus with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This pilot feasibility study aims to examine how the timing of ketamine introduction as a third-line anti-seizure medication infusion relates to seizure cessation in patients with refractory status epilepticus (RSE).
Patients admitted to the Jefferson Neurological Intensive Care Unit with seizures or status epilepticus will be screened for eligibility. Surrogate consent will be obtained from the participants legally authorized representative (LAR) by study personnel for eligible patients using remote e-consent process via RedCap. Participants will be randomized 1:1 to receive either early intravenous ketamine plus midazolam infusion or the current institutional protocol of midazolam followed by late ketamine infusion (Fernandez et al., 2018). Continuous video EEG monitoring will guide medication titration, increasing doses every 20 minutes for ongoing seizure activity. The primary goal of this study is to examine the feasibility of the protocol and obtain estimates of the timing of seizure cessation. The primary outcome is time to seizure cessation, defined as the time from initiation of anesthetic infusion (midazolam or midazolam plus ketamine) to the time of last electrographic seizure. The investigators will also collect preliminary data on other clinical measures that would serve as secondary outcomes for future trials. These clinical measures include progression to super refractory status epilepticus, intensive care unit and hospital length of stay, duration of mechanical ventilation, and functional outcomes assessed by the modified Rankin Scale at discharge, 3 months, and 6 months. This study does not evaluate ketamine as a novel therapy but rather assesses a minor modification in the timing of ketamine administration to optimize seizure control.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with status epilepticus unresponsive to appropriately dosed agents administered intravenous or intraosseous and one second line agent
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Initiation of ketamine infusion simultaneously with midazolam infusion as the third-line anesthetic treatment
Drug: Ketamine · Drug: Midazolam
Initiation of ketamine infusion only after midazolam infusion has been started
Drug: Ketamine · Drug: Midazolam
Time to seizure cessation
Time from initiation of anesthetic infusion (midazolam or midazolam plus ketamine) to the time of last electrographic seizure
Time frame: 72 hours
Plan to share: No
Start is estimated for Nov 2025; primary completion for Jul 2027, 20 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ketamine · Midazolam